Evidence map›Paper›PMID 30695037›Full record

ArticlePloS one2019

Lithium is able to minimize olanzapine oxidative-inflammatory induction on macrophage cells.

Marcelo Soares Fernandes, Fernanda Barbisan, Verônica Farina Azzolin, Pedro Antônio Schmidt do Prado-Lima, Cibele Ferreira Teixeira, Ivo Emílio da Cruz Jung, Charles Elias Assmann, Rogerio Tomasi Riffel, Marta Maria Medeiros Frescura Duarte, Ednea Maia Aguiar-Ribeiro and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Lithium salts as a treatment for COVID-19: Pre-clinical outcomes.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Marcelo Soares FernandesPharmacology Graduate Program, Federal University of Santa Maria, Santa Maria, RS,Brazil.
Fernanda BarbisanGerontology Graduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil.
Verônica Farina AzzolinGerontology Graduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil.
Pedro Antônio Schmidt do Prado-LimaBraIn Institute, Catholic University of Rio Grande do Sul, Porto Alegre-RS, Brazil.
Cibele Ferreira TeixeiraPharmacology Graduate Program, Federal University of Santa Maria, Santa Maria, RS,Brazil.
Ivo Emílio da Cruz JungPharmacology Graduate Program, Federal University of Santa Maria, Santa Maria, RS,Brazil.
Charles Elias AssmannBiochemical Toxicology Graduate Program, Federal University of Santa Maria, Santa Maria, RS, Brazil.
Rogerio Tomasi RiffelFederal University of the Southern Frontier, Passo Fundo, RS, Brazil.
Marta Maria Medeiros Frescura DuartePharmacology Graduate Program, Federal University of Santa Maria, Santa Maria, RS,Brazil.
Ednea Maia Aguiar-RibeiroOpen University of the Third Age, State University of Amazonas, Manaus-AM, Brazil.
Ivana Beatrice Mânica da CruzPharmacology Graduate Program, Federal University of Santa Maria, Santa Maria, RS,Brazil.ORCID 0000-0002-2960-7047
Universidade Federal de Santa Maria · BRHospital Ortopédico de Passo Fundo · BRInstituto do Cérebro · BRUniversidade do Estado do Amazonas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlanzapine (OLZ) is a second-generation antipsychotic drug used for treatment of schizophrenia, bipolar disorder, and other neuropsychiatric conditions. Undesirable side effects of OLZ include metabolic alterations associated with chronic oxidative-inflammation events. It is possible that lithium (Li), a mood modulator that exhibits anti-inflammatory properties may attenuate OLZ-induced oxi-inflammatory effects. METHODOLOGY: To test this hypothesis we activated RAW 264.7 immortalized macrophages with OLZ and evaluated oxidation and inflammation at the gene and protein levels. Li and OLZ concentrations were determined using estimated plasma therapeutic concentrations.

resultsOLZ triggered a significant increase in macrophage proliferation at 72 h. Higher levels of oxidative markers and proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, with a concomitant reduction in IL-10, were observed in OLZ-exposed macrophages. Lithium (Li) exposure triggered a short and attenuated inflammatory response demonstrated by elevation of superoxide anion (SA), reactive oxygen species (ROS), IL-1β, and cellular proliferation followed by elevation of anti-inflammatory IL-10 levels. Li treatment of OLZ-supplemented macrophages was able to reverse elevation of oxidative and inflammatory markers and increase IL-10 levels.

conclusionsDespite methodological limitations related to in vitro protocols, results suggested that Li may attenuate OLZ-induced oxidative and inflammatory responses that result from metabolic side effects associated with OLZ.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalAntipsychotic AgentsCell ProliferationCytokinesInflammationLithiumMacrophagesMiceOlanzapineOxidative StressRAW 264.7 CellsAnti-Inflammatory Agents, Non-SteroidalAntipsychotic AgentsCytokinesLithiumOlanzapine

Identifiers

PMID30695037
PMCPMC6350970
OpenAlexW2913161807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.